Atom | Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Funder: National Institutes of Health (NIH)

Due Dates: October 30, 2025 (anticipated)

Funding Amounts: Award size not specified; third-party matching funds required equal to or greater than NCI request; project period and award ceiling to be specified in NOFO.

Summary: Supports SBIR Phase II awardees in advancing cancer-relevant technologies toward commercialization, with a focus on leveraging third-party investment.

Key Information: Forecasted opportunity; application instructions and full details will be available in Summer 2025.

Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Sign in to see full grant listing